CUTIA-B (02487) announced that its Chief Executive Officer and Executive Director, Zhang Lele, has further increased his shareholding.
Kedi-B (02487) issued an announcement, stating that the Board of Directors of the company received a notice from the company's Chief Executive Officer and Executive Director Zhang Lele...
CUTIA-B (02487) announced that the Board of Directors received a notification from the company's CEO and executive director, Zhang Lele, that he personally purchased a total of 5,200 shares of the company on the open market on November 14, 2024, at a total cost of approximately HK$49,600 (increase in shareholding).
Related Articles
Sichuan Biokin Pharmaceutical (688506.SH): The first subject has been enrolled in the Phase III clinical trial for T-Bren in first-line HER2 mutated non-squamous non-small cell lung cancer.
PAGODA GP (02411) applied for advice on the implementation of full H-share circulation and received a filing notice from the China Securities Regulatory Commission.
On October 20th, ANTON OILFIELD (03337) expended approximately HKD 4.9416 million to repurchase 4.424 million shares.
Sichuan Biokin Pharmaceutical (688506.SH): The first subject has been enrolled in the Phase III clinical trial for T-Bren in first-line HER2 mutated non-squamous non-small cell lung cancer.
PAGODA GP (02411) applied for advice on the implementation of full H-share circulation and received a filing notice from the China Securities Regulatory Commission.
On October 20th, ANTON OILFIELD (03337) expended approximately HKD 4.9416 million to repurchase 4.424 million shares.
RECOMMEND
Why European Automakers Are Opposing Dutch Sanctions
20/10/2025
Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025
Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025
